237 related articles for article (PubMed ID: 16777629)
1. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
Crawford J; Dale DC; Lyman GH
Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
[TBL] [Abstract][Full Text] [Related]
3. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
4. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
Lyman GH; Kuderer NM
Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
[TBL] [Abstract][Full Text] [Related]
5. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
6. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
8. The prevention of febrile neutropenia.
Pascoe J; Cullen M
Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
Lyman GH; Kuderer NM
Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
[TBL] [Abstract][Full Text] [Related]
11. Optimizing the management of chemotherapy-induced neutropenia.
Dale DC
Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
[TBL] [Abstract][Full Text] [Related]
12. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
Bhana N
Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
[TBL] [Abstract][Full Text] [Related]
13. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
[TBL] [Abstract][Full Text] [Related]
14. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
Rader M
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
[TBL] [Abstract][Full Text] [Related]
16. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
Johnston EM; Crawford J
Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
[TBL] [Abstract][Full Text] [Related]
17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
18. [Guidelines for prevention of febrile neutropenia].
Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
[TBL] [Abstract][Full Text] [Related]
19. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
[TBL] [Abstract][Full Text] [Related]
20. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
